Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 5/2011

01.05.2011 | Original article

Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction

verfasst von: Jonathan H. Lee, Yun Chen, Joseph L. Chan, You-wen Qian, James S. Goydos

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Sentinel lymph nodes (SLNs) of melanoma patients show evidence of tumor-induced immune dysfunction. Our previous works have shown that IL-10 and IFNγ co-regulate indoleamine-2,3-dioxygenase (IDO)-expressing immunosuppressive dendritic cells (DCs) in melanoma SLNs. The goal of this study is to examine the relationship between melanoma SLN tumor burden and the degree of SLN immune dysfunction as a model to study tumor-induced immune dysfunction. We hypothesize that SLN tumor burden correlates with the degree of SLN immune dysfunction.

Methods

Patients undergoing SLN biopsy for clinical stages I and II melanomas were enrolled in the study under an IRB-approved protocol. During the SLN biopsy, non-hot and non-blue portion of the SLN was harvested, flash-frozen in liquid nitrogen, and mRNA was extracted. By using quantitative real-time PCR, gene expressions of cytokines (IL-4, IL-10, IFNγ, TGFβ, GM-CSF) and the surrogates of immunosuppressive regulatory and effector cells (IDO-expressing DCs and Foxp3-expressing T-regs, respectively) were measured and correlated against the SLN tumor burden (MART1) and against each other. The data were log transformed for normalization. Statistical test used Student’s t-test and stepwise multivariate regression analysis. Statistical significance was determined at P < 0.05.

Results

SLNs of 74 patients were analyzed in this analysis. Ten of seventy-four patients (13.5%) had tumor-positive SLNs. MART1 gene expression showed a significant difference between the SLN (+) and SLN (−) groups (P = 0.04). Among the various cytokines, multivariate analysis showed that only IFNγ gene expression correlated independently with MART1 gene expression (P < 0.0001, r = 0.91). Similar multivariate analyses show that IFNγ (P < 0.0001, r = 0.78), IL-10 (P = 0.0037, r = 0.60), and TGFβ (P < 0.0001, r = 0.95) gene expressions correlated independently with IDO gene expression. IFNγ (P < 0.0001, r = 0.87) and GM-CSF (P = 0.042, r = 0.76) gene expressions correlated independently with Foxp3 gene expression. MART1 gene expression showed independent correlation with IDO (P = 0.0002, r = 0.75) and Foxp3 (P = 0.0002, r = 0.75) gene expressions.

Conclusion

SLN tumor burden correlates with immunosuppressive IDO and Foxp3 expressions within the SLNs of melanoma patients. Our data are consistent with our theory that melanoma induces expressions of specific cytokines, which in turn, stimulate immune suppressors within the SLN. This study also supports our previous finding that IL-10 and IFNγ co-regulate IDO within the SLN. In our data, IFNγ is the sole cytokine that correlates with the SLN tumor burden and seems to play a central role in tumor-induced immunological changes in the SLN immune microenvironment.
Literatur
1.
Zurück zum Zitat Balch CM et al (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648PubMed Balch CM et al (2001) Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648PubMed
2.
Zurück zum Zitat Balch CM et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 19(16):3622–3634PubMed Balch CM et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 19(16):3622–3634PubMed
3.
Zurück zum Zitat Essner R et al (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139(9):961–966, discussion 966–967PubMedCrossRef Essner R et al (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139(9):961–966, discussion 966–967PubMedCrossRef
4.
Zurück zum Zitat Cochran AJ et al (2004) Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17(7):747–755PubMedCrossRef Cochran AJ et al (2004) Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17(7):747–755PubMedCrossRef
5.
Zurück zum Zitat Starz H, De Donno A, Balda BR (2001) The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 8(Suppl 9):48S–51SPubMed Starz H, De Donno A, Balda BR (2001) The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 8(Suppl 9):48S–51SPubMed
6.
Zurück zum Zitat Lee JH et al (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22(18):3677–3684PubMedCrossRef Lee JH et al (2004) Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22(18):3677–3684PubMedCrossRef
7.
Zurück zum Zitat Morton DL et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4):392–399PubMed Morton DL et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4):392–399PubMed
8.
Zurück zum Zitat Cochran AJ et al (1987) Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 78(3):399–405PubMed Cochran AJ et al (1987) Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 78(3):399–405PubMed
9.
Zurück zum Zitat Cochran AJ et al (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14(6):604–608PubMedCrossRef Cochran AJ et al (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14(6):604–608PubMedCrossRef
10.
Zurück zum Zitat Viguier M et al (2004) Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2):1444–1453PubMed Viguier M et al (2004) Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2):1444–1453PubMed
11.
Zurück zum Zitat Lee JH et al (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11(1):107–112PubMed Lee JH et al (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11(1):107–112PubMed
12.
Zurück zum Zitat Hoon DS, Bowker RJ, Cochran AJ (1987) Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 47(6):1529–1533PubMed Hoon DS, Bowker RJ, Cochran AJ (1987) Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 47(6):1529–1533PubMed
13.
Zurück zum Zitat Munn DH et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 297(5588):1867–1870PubMedCrossRef Munn DH et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 297(5588):1867–1870PubMedCrossRef
14.
Zurück zum Zitat Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase and tryptophan catabolism. FASEB J 5(11):2516–2522PubMed Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase and tryptophan catabolism. FASEB J 5(11):2516–2522PubMed
15.
Zurück zum Zitat Frumento G et al (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 196(4):459–468PubMedCrossRef Frumento G et al (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 196(4):459–468PubMedCrossRef
16.
Zurück zum Zitat Munn DH et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191–1193PubMedCrossRef Munn DH et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191–1193PubMedCrossRef
17.
Zurück zum Zitat Munn DH et al (2004) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280–290PubMed Munn DH et al (2004) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280–290PubMed
18.
Zurück zum Zitat Palucka KA et al (1998) Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160(9):4587–4595PubMed Palucka KA et al (1998) Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160(9):4587–4595PubMed
19.
Zurück zum Zitat Geissmann F et al (2002) Accumulation of immature langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 196(4):417–430PubMedCrossRef Geissmann F et al (2002) Accumulation of immature langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 196(4):417–430PubMedCrossRef
20.
Zurück zum Zitat Belladonna ML et al (2008) Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181(8):5194–5198PubMed Belladonna ML et al (2008) Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181(8):5194–5198PubMed
21.
Zurück zum Zitat Vuylsteke RJ et al (2006) Tumor-Specific CD8+ T cell reactivity in the sentinel lymph node of gm-csf-treated stage i melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 12(9):2826–2833PubMedCrossRef Vuylsteke RJ et al (2006) Tumor-Specific CD8+ T cell reactivity in the sentinel lymph node of gm-csf-treated stage i melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 12(9):2826–2833PubMedCrossRef
22.
Zurück zum Zitat Leong SP et al (2002) Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 9(1):82–87PubMedCrossRef Leong SP et al (2002) Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann Surg Oncol 9(1):82–87PubMedCrossRef
23.
Zurück zum Zitat Lattime EC et al (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41(3):151–156PubMedCrossRef Lattime EC et al (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41(3):151–156PubMedCrossRef
24.
Zurück zum Zitat Kirkwood JM et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial test, 1684. J Clin Oncol 14(1):7–17PubMed Kirkwood JM et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial test, 1684. J Clin Oncol 14(1):7–17PubMed
25.
Zurück zum Zitat Soiffer R et al (2003) Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21(17):3343–3350PubMedCrossRef Soiffer R et al (2003) Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21(17):3343–3350PubMedCrossRef
26.
Zurück zum Zitat Spitler LE et al (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18(8):1614–1621PubMed Spitler LE et al (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18(8):1614–1621PubMed
27.
Zurück zum Zitat Carlson GW et al (2003) The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 10(5):575–581PubMedCrossRef Carlson GW et al (2003) The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 10(5):575–581PubMedCrossRef
28.
Zurück zum Zitat Quezada SA et al (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935–1945PubMedCrossRef Quezada SA et al (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935–1945PubMedCrossRef
Metadaten
Titel
Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction
verfasst von
Jonathan H. Lee
Yun Chen
Joseph L. Chan
You-wen Qian
James S. Goydos
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 5/2011
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-0982-x

Weitere Artikel der Ausgabe 5/2011

Cancer Immunology, Immunotherapy 5/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.